Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose limiting side effect of
many commonly used chemotherapeutic agents, including platinum drugs, taxanes …

12078 Background: Neuropathy is a common side effect of some chemotherapies. Clinical
and other factors may confer neuropathy risk, but rates and risk factors across neuropathy …

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and serious clinical
problem that affects many patients receiving cancer treatment. This condition may pose …

Introduction: Prevention and treatment of chemotherapy-induced peripheral neurotoxicity
(CIPN) are clinically-relevant unmet needs. Despite extensive efforts at the preclinical and …

Central and especially peripheral neurotoxicities due to systemic antineoplastic therapy are
common and often dose-limiting side-effects. In patients with chemotherapy (ChT)-induced …

Chemotherapy-induced peripheral neuropathy (CIN) is a common toxicity of anticancer
treatment and its incidence is growing. It significantly affects quality of life and is a dose …

Opinion statement Although progress in cancer research is paralleled by the discovery and
development of novel chemotherapeutic agents, the benefits of these agents are offset by …

The development of neurotoxicity during antineoplastic therapy is one of the most common
reasons for termination or modification of cancer treatment. A number of different agents …

Introduction: Chemotherapy-induced peripheral neuropathy (CIPN), a common adverse
effect of several chemotherapeutic agents, has a significant impact on quality of life and may …